New Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains

/PRNewswire/ -- FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the...

Related Keywords

Tokyo ,Japan ,Belgium ,Yoshihiro Kawaoka ,Pabout Flugen ,Flugen Inc ,Infectious Diseases ,Influenza Research Institute ,Medical Science ,Single Replication ,Vaccine Provides Enhanced Mucosal ,Serum Antibodies ,Live Virus Vaccine ,